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Abstract. – OBJECTIVE: To assess the asso-
ciation of clinicopathologic and molecular fea-
tures with loco-regional recurrence (LRR) in 
post-mastectomy breast cancer patients with or 
without adjuvant radiotherapy (PMRT).
PATIENTS AND METHODS: We retrospectively 
reviewed data of patients undergone to mastec-
tomy followed or not by PMRT between January 
2004 and June 2013. The patients were divid-
ed according to clinicopathologic and molecu-
lar sub-classification features. LRR and Cancer 
Specific Survival (CSS) were calculated using 
the Kaplan-Meier method; the prognostic fac-
tors were compared using long-rank tests and 
Cox regression model. 
RESULTS: A total of 912 patients underwent 
to mastectomy of whom 269 (29.5%) followed 
by PMRT and 643 (70.5%) not; among the PM-
RT group, 77 underwent to the chest wall (CW) 
and 202 to the chest wall and lymphatic drainage 
(CWLD) irradiation. The median follow-up was 54 
months (range, 3-118). 
No significant difference in terms of LRR and 
CSS was found between non-PMRT and PMRT 
group (p=0.175; and p=0.628). The multivariate 
analysis of LRR for patients who did not under-
go PMRT showed a significant correlation with 
the presence of extracapsular extension (ECE) 
(p=0.049), Ki-67>30% (p=0.048) and triple neg-
ative status (p=0.001). In the PMRT group, tri-
ple negative status resulted as the only variable 
significantly correlated to LRR (p=0.006) at the 
multivariate analysis and T-stage also showed a 
trend to significance (p=0.073). Finally, no differ-
ence in LRR control was shown between CW and 
CWLD-PMRT (p=0.078).
CONCLUSIONS: After mastectomy ECE, a cut 
off of Ki-67>30% and triple negative status were 
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strictly correlated with LRR regardless of clinico-
pathologic stage. PMRT has a positive impact in 
decreasing LRR in patients with this molecular 
profile. Besides, CW might represent a valid op-
tion for patients with one to three positive nodes. 
Key Words: 
Post-mastectomy radiotherapy, Locoregional recur-
rence, Clinicopathological factors.
Introduction
The role of conservative surgery has already 
been well established by many studies as it repre-
sents the milestone of treatment for early breast 
cancer despite mastectomy remains a validated 
therapeutic option1-8. Data resulting by the Na-
tional Surgical Quality Improvement Program 
database on 85401 breast cancer showed an incre-
ase incidence of mastectomy over breast-conser-
ving surgery from 2005 to 2011, starting at 40% 
and peaking to 51% (p<0.001), probably due to 
the more bilateral resection, immediate recon-
struction, and prophylactic operations9. 
The role of radiotherapy after mastectomy 
(PMRT) has also been defined by several large 
randomized trials and meta-analysis showing a 
benefit in terms of locoregional control and ove-
rall survival in patients affected by local advan-
ced disease10-14. The American Society of Clinical 
(ASCO) and the American Society of Therapeutic 
Radiology and Oncology (ASTRO) recommended 
the use PMRT for patients whose primary tumors 
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are larger than 5 cm (T3 disease) and those with 
four or more positive nodes. Recently, an Early 
Breast Cancer Trialists’ Collaborative Group me-
ta-analysis showed that patients with 1-3 positi-
ve axillary nodes benefited from PMRT, even in 
combination with systemic therapy15. Instead, a 
randomized clinical study by the European Or-
ganization for Research and Treatment of Cancer 
(EORTC) showed that the same group of women 
did not have a clear survival benefit16. That being 
so, several doubts remain regarding the role of 
PMRT and selection of patients. 
Various clinicopathologic features (i.e. age <40 
years; lymphovascular invasion) have been studied 
regardless of the T and N stage17-27. Furthermore, 
a general consensus regarding the PMRT volumes 
has not yet been reached28. In fact, despite the chest 
wall (CW) is recognized as the area at greatest risk 
of recurrences after mastectomy, most data recom-
mend to extend RT field to the regional lymphatic 
drainage (CWLD-PMRT), such as apex axilla and 
supraclavicular nodes regardless nodal status. This 
is likely because existing data support an extended 
treatment in more advanced disease whereas the 
role of CW-PMRT in the intermediate stage has 
been poorly investigated yet28,29.
The purpose of this study was to associate cli-
nicopathologic and molecular features with lo-
co-regional recurrences (LRRs) in a large cohort 
of patients undergone to mastectomy with or 
without PMRT. Secondarily, we analyzed and 
compared the pattern of LRR between CW and 




The cases of breast cancer patients who were 
diagnosed and treated at University Hospital of 
Pisa between January 2004 and June 2013 were 
retrospectively reviewed. This study was appro-
ved by institutional Review Boards and carried 
out as a collaboration of Breast Surgery, Radiation 
Oncology and Medical Oncology Departments.
We reviewed data of patients who underwent a 
total mastectomy followed by sentinel node exa-
mination ± axillary dissection. 
Mastectomy was performed in the presence of 
one or more of the following clinical situations:
 1. Retroareolar tumor location
 2. Multicentricity
 3. Local advanced disease (cT3-4 and/or cN2-3) 
 4. Inflammatory breast cancer 
 5. Unfavorable tumor size/breast volume ratio
In patients affected by inflammatory breast 
cancer, mastectomy was always performed after 
primary chemotherapy and combined with axil-
lary dissection30. 
According to the literature data, patients un-
derwent to CW or to CWLD-PMRT depending 
on the pathological nodal status31,32. 
Salvage mastectomy for local recurrence after 
a previous conservative surgery and RT, as well 
as presence of systemic disease at diagnosis, was 
considered exclusion criteria of the study. All pa-
tients provided written consent for storage and re-
search use of their medical information.
Clinicopathologic and Molecular 
Features 
Classification of histologic type (ductal carci-
noma not otherwise specified, lobular carcinomas 
or other types), histologic grade, measurement of 
size, invasion of the tumor into the skin or the deep 
fascia and number of removed and positive axil-
lary nodes were evaluated and reported. We used 
the histologic tumor grade obtained by pathology 
review and estrogen and progesterone receptors 
(ER and PgR) and Her2 status extracted from 
pathology reports. Her2 was considered positive 
if immunohistochemical stains were reported 3+ 
and/or if Her 2 FISH showed gene amplification. 
Ki-67 was assessed immunohistochemically. The 
percentage of positive cells (nuclear immunore-
activity) among 2000 randomly selected tumors 
cells viewed at 400x at the periphery of the tu-
mor, was calculated; Ki-67 was categorized as 
low (<30%) or high (≥30%). 
Adjuvant Treatment Details
When performed, RT was delivered by a line-
ar accelerator with a tridimensional conformal 
(3DCRT) or static IMRT technique. The prescri-
bed dose was 50 Gy delivered in 25 fractions ad-
ding a boost of 20 Gy and 14-16 Gy for positive 
and close (<2 mm) surgical margins, respectively.
Adjuvant chemotherapy was mostly performed 
using CMF or FEC scheme followed by weekly 
taxol; PMRT was always deferred until the com-
pletion of chemotherapy.
Tamoxifen, alone or combined with LHRH 
agonist (for post and pre-menopausal patients 
respectively), as well as aromatase inhibitors or 
switch regimen (Tamoxifen for 3 years followed 
by aromatase inhibitors for 2 years) was used in 
hormone responsive tumors. Finally, trastuzumab 
was administered in all patients with Her-2/neu 
overexpression or FISH amplification, concomi-
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tant to taxanes based chemotherapy regimens or 
sequential to chemotherapy as monotherapy. 
Follow-up
According to our protocol, we evaluated pa-
tients at 3-month intervals for 2 years and every 6 
months thereafter for a total of 5 years. All the pa-
tients analyzed for the study received at least two 
follow-up visits. Evaluations consisted of physical 
examination, complete blood cell counts and blood 
chemistry exams including CEA and Ca15.3 level 
at every follow-up visit, mammography scan and/or 
liver ultrasound after six months and then annually.
LRR was defined as the time interval between 
the date of mastectomy and recurrence (confir-
med histologically) or the last follow-up contact 
with the patient and was distinguished into local 
(chest wall) and/or regional relapses (axilla, su-
pra-clavicular, internal mammary nodes). Distant 
metastasis was defined as failure beyond the local 
or regional area. Cancer specific survival (CSS) 
was defined as the time interval between the date 
of diagnosis and the date of cancer-related death 
or the last follow-up contact.
Statistical Analysis
Survival curves were calculated using the 
Kaplan-Meier method, and the log-rank test was 
used to evaluate the differences among the curves. 
Eight prognostic factors were assessed: T sta-
ge (T1-T2 vs. T3-T4), N stage (N0-N1 vs. N2-N3), 
extracapsular extension; lymphatic vascular inva-
sion; triple negative profile; Her2/neu status; Ki-
67 (≤30% vs. >30%); grading (G1-2 vs. G3).
Univariate survival analysis was performed in-
cluding each variable in a Cox regression model 
and calculating related p-value by Wald test. All 
variables significantly influencing survival in the 
univariate analysis were analyzed together in a 
Cox regression model as multivariate analysis, 
with the aim of studying the independent contri-
bution of each variable in explaining survivorship. 
Five different variables were tested as inde-
pendent prognostic factors: age (≤40 vs. >40); 
receptor expression; focality (unifocal vs. multi-
focal/multicentric disease); neoadjuvant chemo-
therapy; adjuvant chemotherapy. 
Furthermore, the proportional hazard was always 
verified by the use of log(-log) curves. The results 
of the Cox regression were expressed using hazard 
ratios with related confidence intervals and related 
p-value. Differences were considered significant at 
p<0.05 and analyses were performed using SPSS 22 
(SPSS Inc., Chicago, IL, USA) technology.
Results
Overall, 912 patients underwent a total mastec-
tomy followed or not by PMRT and were analyzed. 
Patients, tumor characteristics and treatment details 
are shown in Table I. For the entire study population, 
the median follow-up was 54 months (range, 3-118). 
Table I. Patients characteristics, biological tumor factors 
and systemic treatment details.
 No PMRT  PMRT  
Total patients 643 (70.5%)  269 (29.5%)
Age   
Median 54  56
≤ 40 46 (7.2%)  21 (7.4%)
> 40 597 (92.8%)  249 (92.6%)
Extra capsular extension   
Yes 19 (2.9%)  90 (33.4%)
No 542 (84.2%)  174 (64.7%)
Unknown 82 (12.9%)  5 (1.9%)
Lymphatic vascular invasion   
Yes 63 (90.2%)   82 (30.5%)
No 580 (19.8%)  187 (69.5%)
Triple negative 
Yes 35 (5.5%)  14 (5.3%)
No 548 (85.2%)  239 (88.8%)
Unknown 60 (9.3%)  16 (5.9%)
HER2/neu status 
Negative 492 (76.5%)  204 (75.8%)
Positive 79 (12.3%)  44 (16.3%)
Unknown 72 (11.2%)  21 (7.9%)
Mib 1   
≤ 30% 433 (67.3%)  191 (71%)
> 30% 143 (22.2%)  59 (21.9%)
Unknown 67 (10.5%)  19 (7.1%)
Grading   
G1-2 226 (35.1%)  67 (24.9%)
G3 280 (43.5%)  150 (55.8%)
Unknown 137 (21.4%)  52 (19.3%)
T-stage   
T1-T2 534 (83%)  168 (62.4%)
T3-T4 40 (6.3%)  83 (30.8%)
Unknown 69 (10.7%)  18 (6.8%)
N-stage   
N0-N1 555 (86.3%)  106 (39.4%)
N2-N3 6 (1%)  158 (58.7%)
Unknown 82 (12.7%)  5 (1.9%)
Neoadiuvant chemotherapy   
Yes 66 (10.3%)  95 (35.3%)
No 577 (89.7%)  174 (64.7%)
Adiuvant chemotherapy   
Yes 367 (57%)  202 (75.1%)
No 276 (43%)  67 (24.9%)
Hormonotherapy   
Yes 473 (73.6%)  222 (82.5%)
No 170 (26.4%)  47 (17.5%)
Abbreviations: PMRT = post mastectomy radiotherapy; 
ECE=Extracapsular extension; LVI=Lymphatic vascular invasion.
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Distribution of Clinicopathologic  
Features Among Different  
Molecular Subtypes
The percentage of T1-2 stage was 77% (702/912) 
against 13% (123/912) of T3-4. Among T1-2 pa-
tients 55% (386/702) were affected by a multifo-
cal or multicenter disease and 45% (317/702) by a 
unifocal disease. Additionally, 692 patients (76%) 
were affected by a receptor expressing disease, 
123 patients (13%) by a Her-2 positive disease and 
49 patients (5%) by a triple negative disease, whe-
reas 57/123 patients (46%) were affected by a Her-
2 positive non-luminal disease.
Adjuvant and Neoadjuvant Treatment
Overall 161/912 patients (18%) underwent neo-
adjuvant chemotherapy, and 11/161 (6.83%) were 
affected by an inflammatory breast cancer dise-
ase. Moreover, in the neoadjuvant chemotherapy 
group 11/161 (6.83%) patients also experienced a 
complete pathological remission both on T and N, 
and 15/161 (9.3%) the residual of single or multi-
ple in situ foci. RT was delivered postoperatively 
in 269 patients of whom 77 underwent to CW-
PMRT and 202 to CWLD-PMRT.
Distant Metastases, Cancer-Specific 
Survival (CSS) and Tumor Recurrences 
For the entire study population, the 5-10 year 
locoregional free survival (LRFS) rates were 
94% and 93%; the 5-10 year CSS and OS rates 
were 93%, 80% and 92%, 71,5%, respectively. 
Of the 46 locoregional recurred patients, 22 
(48.5%) also experienced a subsequent distant 
progression; additionally, among the 22 patien-
ts who experienced locoregional recurrence 
and distant progression disease 15 (68%) died 
due to cancer. 
The median time between the time of recurren-
ce and distant progression was 6 months (range, 
2-25 months) and between distant progression and 
death was 10 months (range, 1-61 months). 
Overall, 31/643 (4.8%) in non-PMRT group 
experienced a locoregional relapses against 15/269 
(5.5%) in PMRT group; specifically, 19 were local, 
7 regional and 5 both local and regional in non-
PMRT group whereas 9 local, 4 regional and 2 
both local and regional in PMRT group. 
Stratified Analysis of Tumor Recurrence 
The patients’ clinicopathologic characteristics 
are shown in Table I according to the treatment 
received. No differences were found between pa-
tients with or without PMRT for LRR (p=0.175; 
HR=1.613; CI95%=0.808-3.219); this comparison 
is reported in Figure 1.
The univariate analysis of LRR for patients 
not undergone PMRT showed a significant cor-
relation with the presence of ECE (p=0.031), 
Ki-67>30% (p=0.010), triple negative status 
(p<0.0001), T stage (p=0.009) and N stage 
(p=0.001); at the subsequent multivariate analysis 
ECE, Ki-67>30% and triple negative status main-
tained a statistical significant value (p=0.049 for 
Figure 1. Comparison of locoregional recurrence free survival for PMRT and no-PMRT group of patients.
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ECE; p=0.048 for Ki-67>30% and p=0.001 for 
triple negative). No correlation was found in the 
non-PMRT group with age (p=0.636) and focali-
ty (p=0.880), a trend to significance resulted for 
neoadjuvant (p=0.067) and adjuvant chemothe-
rapy (p=0.073), whereas a statistical correlation 
was found with receptor expression (p<0.0001; 
HR=0.172; CI=0.064-0.461).
Differently, in the PMRT group only the triple ne-
gative status and T stage resulted significantly cor-
related to LRR (p<0.0001 and p=0.008, respecti-
vely) at the univariate analysis; at the subsequent 
multivariate analysis the triple negative maintained 
a significant value (p=0.006) whereas the T stage 
showed a trend to significance (p=0.073). These re-
sults are clearly shown in Table II.
No correlation was found with age (p=0.280), 
focality (p=0,734), neoadjuvant (p=0.100) and 
adjuvant chemotherapy (p=0.195), whereas a stati-
stical correlation was found with receptor expres-
sion (p<0.0001; HR=0.105;CI=0.034-0.319). 
CW-PMRT and CWLD-PMRT
Among 269 PMRT patients, 77 underwent to 
CW-PMRT and 202 to CWLD-PMRT. 
As reported in Figure 2, no statistical significant 
difference was shown for CWLD against CW-
PMRT for LRR (p=0.078; HR=0.375; CI95%= 
0.126-1.116).
In detail, in the CWLD group 8/198 (4%) pa-
tients experienced LRR; 3 patients reported local, 
3 regional and 2 both local and regional relapses 
whereas in the CW group 7/67 (10.5%) patients 
experienced LRR relapses of whom 6 patients 
reported local and only one an isolated regional 
relapse.
Among the CW-PMRT relapses, 2 were pN1 (one 
with 2/15 and the other with 2/9 positive nodes) 
and 5 patients were pN0 (among which the only 
one who experienced isolated regional failure).
Moreover, two patients had a T4 and T3 disease at 
the primary diagnosis and underwent neoadjuvant 
chemotherapy before mastectomy and PMRT.
On the contrary, among the CWLD-PMRT relap-
sed patients, 2 were affected by an inflammatory 
breast cancer disease and 3 by a T3 disease whe-
reas 4 patients were N3 and 4 patients were N2 at 
the initial diagnosis; all patients with T4 and/or 
N3 underwent to neoadjuvant chemotherapy.
Of the 3 regional relapses, two patients were 
N3 and one patient was N2 whereas of the 2 com-
bined local and regional relapses, one was T4d N2 
and the other was T1cN2. 
Finally, of the 3 local relapses, one patient was 
affected by a T3N2, one patient by a T2 N3 and 
another one by a T3 N3 disease.
Discussion
Long time ago, molecular typing became a stan-
dard assessment in clinical practice for the guidance 
of chemotherapy and endocrine therapy in patients 
with breast cancer33,34. On the contrary, few studies 
Figure 2. Comparison of locoregional recurrence free survival for CW and CWLD group of patients.
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have analyzed the utility of molecular typing in RT, 
especially to guide decisions regarding PMRT.
Eight clinicopathologic variables (ECE; LVI; 
Triple negative; Her2 neu; Ki-67; Grading; T-sta-
ge and N-stage) were analyzed in patients treated 
or not with PMRT. In no PMRT group, the presen-
ce of ECE, triple negative status and Ki-67>30% 
resulted as independent prognostic factors of 
LRR. In detail, the role of ECE has been poorly 
investigated as prognostic factors in breast cancer 
and the few available literature data identified a 
significant correlation of this factor with a lower 
probability of disease-free survival. The retro-
spective study by Hetelekidis et al35 was under-
taken to investigate whether ECE of axillary node 
metastases was a predictive factor of disease or 
regional recurrence-free survival in early breast 
cancer. At first, patients with ECE were more 
likely to have a lower oncologic outcome as the 5 
year disease free survival rates resulted 67% for 
patients without ECE and 57% for patients with 
ECE (p=0.05). However, ECE failed to maintain a 
significant prognostic value when combined with 
the other prognostic factors (such as T stage, LVI, 
number of positive nodes, etc.) in a proportional 
hazard model (p=0.64 for disease-free survival in 
the multimodel regression). Moreover, as report-
ed by several other studies after mastectomy36-38, 
authors specified that the prognostic value of 
ECE is strictly correlated to the number of pos-
itive nodes so that in the multivariate analysis, 
ECE was correlated with a decreased survival, 
Table II. Univariate and multivariate (Cox model) analysis of the LRR prognostic factors. 
LRR Univariate Analysis Multivariate Analysis 
                                  No PMRT
Prognostic factors p HR CI 95% p HR CI 95%
ECE
(0) no; (1) yes 0.031 3.503 1.050-15.45 0.049 3.481 1.196-27.95
LVI 
(0) no; (1) yes 0.206 2.039 0.675-6.153   
Triple negative
(0) no; (1) yes <0.0001 8.809 3.030-25.61 0.001 8.427 2.328-30.50
HER2/neu status
(0) negative; (1) positive 0.740 0.778 0.177-3.425   
Ki-67
(0) ≤30%; (1)>30%  0.010 3.692 1.375-9.915 0.048 3.310 1.009-10.86
Grading
(0) G1-2; (1) G3 0.254 1.836 0.647-5.214   
T-stage                                                
(0) T1-T2; (1) T3-T4 0.009 5.666 1.555-20.64    0.697   1.547    0.172-13.89
N-stage
(0) N0-N1; (1) N2-N3 0.001              11.13 2.527-28,98             0.246                  5.174    0.321-29.83
                                  PMRT
ECE
(0) no; (1) yes  0.197 0.430 0.120-1.550   
LVI 
(0) no; (1) yes  0.169 2.089 0.732-5.962            
Triple negative
(0) no; (1) yes  <0.0001 12.27 3.022-49.78    0.006    9.259 1.899-27.14
HER2/neu status
(0) negative; (1) positive  0.322 1.817 0.557-5.929                 
Ki-67
(0) ≤30%; (1)>30%  0.072 2.721 0.914-8.101       
Grading
(0) G1-2; (1) G3  0.250 37.96 0.077-99.80   
T-stage
(0) T1-T2; (1) T3-T4  0.008 4.483          1.446-13.90              0.073    3.064 0.900-10.43
N-stage 
(0) N0-N1; (1) N2-N3  0.148  0.458 0.159-1.321   
Abbreviations: LRR=Locoregional recurrence; PMRT=post-mastectomy radiotherapy; 
ECE=extracapsular extension; LVI=Lymphatic vascular invasion. 
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although with less importance than the number of 
involved nodes (p=0.054 and 0.003, respectively). 
Thus, we believe that our findings are consistent 
with results reported by the few prior studies and 
probably reinforce the prognostic value of ECE 
because it was maintained at the multivariate 
analysis. 
The role of the cancer cell proliferation has been 
well acknowledged and validated in a large num-
ber of studies and several meta-analyses39-44. A re-
cent retrospective study by Pathmanathan et al45 
on 203 node negative patients treated with breast 
conserving surgery and adjuvant radiation with-
out systemic therapy, found out an independent 
prognostic role of value >14% (p=0.005) together 
with the presence of LVI (p=0.003) for breast can-
cer specific survival. Of note, authors reported a 
striking difference in the 15-year mortality rate 
between low and high group (97% compared to 
78%; p=0.0003). Our results confirm the prog-
nostic value of this factor for locoregional con-
trol rather than cancer specific survival reporting 
a cut off of 30% for Ki-67 to be prognostically 
discriminative across the entire cohort of patients.
It is important to note that the two prognostic 
variables failed to maintain the significance in the 
group of women treated with PMRT. In fact, at 
the multivariate analysis in the PMRT group, only 
the triple negative status resulted in a significant 
prognostic variable. 
The benefit of PMRT in the triple negative sub-
set of breast cancer patients has not already been 
definitely established tough a general agreement 
exists regarding the higher risk of locoregional re-
currence compared to other molecular subtypes45. 
Several retrospective studies46 showed that PMRT 
was associated with a lower local recurrence rate 
in triple negative patients even in early stage (T1-
2 N0). Interestingly, in the multicentre prospec-
tive trial by Wang et al47 on 681 early stage triple 
negative patients randomized to receive adjuvant 
chemotherapy with or without radiotherapy, a 
longer disease, and overall survival was observed 
in the radiotherapy group. Similarly, a recent 
retrospective analysis by Chen et al9 reported a 
benefit in terms of locoregional control and dis-
ease-free survival in intermediate (T1-2 N1) and 
high risk (T3-4 and/or N2-3) triple negative pa-
tients. Differently, data reported by a subgroup 
analysis from the Danish Breast Cancer Coopera-
tive Group (DBCTCG 82b and c) showed that tri-
ple negative patients received a lower benefit from 
PMRT than patients with luminal subtypes as an 
higher LRR risk was observed in both randomiza-
tion arms (32% against 15% locoregional relapses 
at 15 years)48. Therefore, it is likely to suggest a 
radioresistant phenotype of triple negative cancer.
In our study, the triple negative status was the 
only variable to maintain a clear statistically sig-
nificance at the multivariate analysis. 
Even so, despite the low sample size of triple 
negative in our cohort of patients (5.3%) did not 
make possible a direct comparison of the two 
groups, our results seem to show a poor benefit 
of radiotherapy in this subset of patients (5/35 
locoregional recurrences in non PMRT group 
against 3/14 in the PMRT group; p=0.863) proba-
bly supporting the radioresistance hypothesis. 
A surprising result of this study endorsed the 
positive role of PMRT in patients with high-risk 
clinicopathologic features and molecular subclas-
sification. The lack of statistical significant dif-
ference for LRR between PMRT and no PMRT 
groups of patients (p=0.175) emphasizes the role 
of radiotherapy in women after mastectomy.
Finally, in the analysis of patients who under-
went radiotherapy a lack of significant difference 
in terms of locoregional relapses between CW 
and CWLD was found. Whether limit the radi-
ation field to the chest wall or extend to the lym-
phatic drainage in less advanced disease has been 
addressed by several studies but is still largely 
unresolved due to the retrospective nature and a 
small number of patients. Briefly, most data re-
port the chest wall as the highest risk site of lo-
cal recurrence35,36,49 as well as a very low rate of 
regional failure after mastectomy in intermediate 
breast cancer disease38,49-51. Thus, in this subset of 
patients, the irradiation of lymphatic areas might 
be avoided with a consequent reduction of poten-
tially side effects. Stranzl et al50 firstly reported 
data on RT limited to the CW on 37 patients who 
underwent mastectomy concluding that treatment 
was enough for patients with the T1-3 N1 disease. 
A more recent retrospective experience by Mac 
Donald et al28 on 238 stage II (one to three nodes) 
patients who underwent mastectomy showed a 
benefit of PMRT in terms of LRR and disease 
free survival (p=0.02 and 0.03) that was similar 
for those treated to the CW alone or to the CW 
and lymphatic drainages. 
In our work, as previously reported, all re-
curred CW-PMRT patients were N0-1 whereas 
CWLD-PMRT patients were T3-4 and/or N2-3; 
no differences in the site of relapses was observed 
in the CWLD group (3 local, 3 regional and 2 both 
local and regional) whereas 6 of the 7 relapses in 
the CW group were local and only one regional. 
S. Ursino, F. Fiorica, V. Mazzotti, D. Delishaj, A. Cristaudo, S. Spagnesi, et al.
2164
Conclusions
Besides the retrospective nature of this study, 
we do believe that our findings have a clinical re-
levance as they further consolidate the positive 
impact of radiotherapy in breast cancer despite 
radical surgery and bring out the possible progno-
stic value of ECE and Ki-67 that might be wron-
gly undervalued in clinical practice. Furthermore, 
our results seem to suggest that CW irradiation 
might represent a reasonable option in certain cir-
cumstances of T1-2 N1 disease after mastectomy.
Prospective studies are needed to properly va-
lidate these results.
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